• Explore the evolution of AI from task-focused tools to foundation and agentic systems transforming drug discovery and development • Gain practical strategies for building scalable, compliant, and effective AI solutions that accelerate R&D outcomes
Numerion Labs is an AI-native company accelerating the discovery of life-saving medicines through the development and use of cutting-edge ML technologies. The company unites computational chemistry, structural biology, and medicinal chemistry to pioneer the next generation of AI-driven drug discovery platforms.
Numerion Labs is an AI-native company accelerating the discovery of life-saving medicines through the development and use of cutting-edge ML technologies. The company unites computational chemistry, structural biology, and medicinal chemistry to pioneer the next generation of AI-driven drug discovery platforms.
Numerion Labs is an AI-native company accelerating the discovery of life-saving medicines through the development and use of cutting-edge ML technologies. The company unites computational chemistry, structural biology, and medicinal chemistry to pioneer the next generation of AI-driven drug discovery platforms.
Key Takeaways:
Steve Worland, Ph.D. serves as the CEO of Numerion Labs (formerly Atomwise) and has over 30 years of experience in corporate leadership and pharmaceutical R&D. He was previously President, CEO, and Board Member of eFFECTOR Therapeutics, which he co-founded in 2012. Prior to that, he was CEO of Anadys Pharmaceuticals, where he led the company through its acquisition by Roche in 2011. Before becoming CEO, he served as Chief Scientific Officer and President of Pharmaceuticals at Anadys.
Earlier in his career, he held senior positions at Agouron Pharmaceuticals, Warner-Lambert, and Pfizer, where his scientific research contributed to the discovery and development of Paxlovid (nirmatrelvir), Inlyta (axitinib), zotatifin, tomivosertib, and other clinical-stage candidates. At Agouron, he was Vice President and Director of Molecular Biology and Biochemistry, remaining at the company through its acquisitions.
Dr. Worland earned a Ph.D. in Chemistry from the University of California, Berkeley, and completed a postdoctoral fellowship in Molecular Biology at Harvard University as an NIH fellow. He earned a B.S. with Highest Honors in Biological Chemistry from the University of Michigan. He serves on the Board of Directors at Blacksmith Medicines and has previously served on the boards of Tracon Pharmaceuticals, Forge Therapeutics, and GenMark Diagnostics.
Numerion Labs is an AI-native company accelerating the discovery of life-saving medicines through the development and use of cutting-edge ML technologies. The company unites computational chemistry, structural biology, and medicinal chemistry to pioneer the next generation of AI-driven drug discovery platforms.
This session will give an understanding of what it takes to realize the vision of fully integrated and autonomous drug discovery, both from an AI and data generation perspective.
Together with our colleagues, customers and stakeholders, we impact life and health with science. Before researchers can make scientific breakthroughs, they must have access to state-of-the-art tools, services and expertise to perform experiments and engineer new products. That’s where we come in.
We offer one of the broadest portfolios in the industry for scientists, best-in-class products for pharmaceutical development and manufacturing, and a fully integrated service organization to support CDMO and contract testing across traditional and novel modalities.
Our vision is a world where our innovative products, services and digital offerings help create solutions for people globally and a sustainable future for generations to come.
The life science business of Merck KGaA, Darmstadt, Germany, operates as MilliporeSigma in the US and Canada. Merck KGaA, Darmstadt, Germany is a global science and technology company with around 60,000 employees in more than 66 countries.
AI’s potential in clinical research extends beyond scientific data to the operational information that underpins every trial. When harnessed effectively, this data reveals patterns in study design, site performance, and execution that can accelerate development and improve outcomes. This session explores how AI and operational insights can reshape the future of clinical research.
Mike Eckrote is Senior Vice President of Strategic Solutions & Technology at Advarra, where he leads efforts to advance innovative approaches to clinical research and development. He brings more than a decade of experience in real-world data, technology solutions, and clinical trial optimization, with leadership roles spanning HealthVerity, Medable, and Medidata Solutions. Throughout his career, Mike has specialized in applying AI/ML, real-world evidence, and data-driven strategies to improve trial design, site selection, and patient outcomes.
Advarra breaks the silos that impede clinical research, aligning patients, sites, sponsors, and CROs in a connected ecosystem to accelerate trials. Advarra is number one in research review services, a leader in site and sponsor technology, and is trusted by the top 50 global biopharma sponsors, top 20 CROs, and 50,000 site investigators worldwide. Advarra solutions improve collaboration, transparency, and compliance to optimize study design and operations. With unmatched trial operations data, and an ongoing investment in AI innovation, Advarra continues to reimagine what’s possible in clinical research. For more information, visit advarra.com.
The promise of AI in pharma is hindered by fragmented R&D data silos and the infrastructure gap between cloud-native research and on-premise manufacturing. This session presents an architectural blueprint for a unified, hybrid data platform designed to bridge these divides, creating a seamless R&D-to-manufacturing continuum.
We will explore how to first connect R&D data into a powerful knowledge graph. Next, we detail how to compute on this unified data by securely deploying NVIDIA's advanced AI models as microservices within a sovereign cloud environment. Finally, we demonstrate how a true hybrid architecture can bridge the cloud-native lab to the factory floor, unifying CMC and manufacturing data for end-to-end optimization.
Cloudera is a hybrid platform for data, analytics, and AI. With 100x more data under management than other cloud-only vendors, Cloudera empowers global enterprises to transform data of all types, on any public or private cloud, into valuable, trusted insights. Our open data lakehouse delivers scalable and secure data management with portable cloud-native analytics, enabling customers to bring GenAI models to their data while maintaining privacy and ensuring responsible, reliable AI deployments. The world’s largest brands in financial services, insurance, media, manufacturing, and government rely on Cloudera to use their data to solve what once seemed impossible—today and in the future.
